Prof. dr. Peter van de Kerkhof


Home Prof. dr. Peter van de Kerkhof
Home About N4i N4i Research Themes Principal Investigators Grants and Awards Grant Calendar High-impact papers N4i Clinical centres N4i Education Students & Postdocs Job Opportunities RUN-MC Institutes Contact News	Prof. dr. Peter van de Kerkhof Current understanding of the modulation of the immune response has permitted the development of pathogenesis based treatments for psoriasis. The research line is focused on (i) a better understanding of the immune system in psoriasis (ii) characterization of efficacy and safety of innovative treatments for this disease (iii) correlation of the clinical characteristics with the parameters for the changes in the immune system. For the next 3 years the following targets have been defined: ‐ the role of regulatory T cells and host defense proteins during early and late phases of the pathogenesis of psoriasis ‐ the efficacy and safety aspects of anti TNF treatments, anti IL‐12/23 treatments and anti ‐IL17 treatments ‐ the value of characteristics of Treg and host defense proteins as biomarkers Recent key publications Evers AWM, Verhoeven EWM, Kraaimaat, FW, de Jong EMGJ, de Brouwer SJM, Schalkwijk J, Sweep FCGJ, van de Kerkhof, PCM. How stress gets under the skin: cortisol and stress reactivity in psoriasis. British Journal of Dermatology, 163: 986‐991, 2010 Driessen RJB, Bisschops, LA, Adang EMM, Evers AW, van de Kerkhof PCM, de Jong E MG J The economic impact of high‐need psoriasis in daily clinical practice before and after the introduction of biologics. British Journal of Dermatology 162: 1324‐1329, 2010 van de Kerkhof PCM, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, Saari S, Segaert S, Vaillant L. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology, 60: 170‐176, 2009 Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, Menter A, Van de Kerkhof PCM. Psoriasis: Improving adherence to topical therapy. Journal of the American Academy of Dermatology, 59 : 1009‐1016, 2008 van de Kerkhof PCM, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba, A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial with open‐label extension. British Journal of Dermatology, 159 : 1177‐ 1185,2008 .	Prof. dr. Peter van de Kerkhof is head of the department Dermatology at the Radboud University Nijmegen Medical Centre, The Netherlands. He graduated in medicine from the Catholic University of Nijmegen in 1978 and trained in Dermatology at the St. Radboud Hospital, Nijmegen. In 1983 and in 1990 he completed his theses in the faculty of medicine and faculty of sciences resp. Between 1980 and 1984 he completed his training as a dermatologist.